Cardiac division underperformance vs IPM
Cardiology growth has been lower than IPM due to competitive intensity and market share loss; management expects recovery in 2-3 quarters.
medium · analyst_question
Ajanta Pharma Limited — Q1 FY26
Ajanta Pharma delivered a 14% revenue growth to INR 1,303 crore in Q1 FY26, driven by a 36% surge in US generics (INR 310 crore) and 16% India growth (INR 409 crore).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Africa branded business growth moderation
Africa sales were flat YoY in Q1 due to high base from 28% growth last year; full-year guidance of mid-to-high single-digit growth may be at risk if headwinds persist.
medium · management_commentaryForex volatility impacting profitability
INR 25 crore mark-to-market forex loss in Q1 due to euro movement; further volatility could pressure margins.
medium · management_commentaryElevated other expenses weighing on margins
Other expenses grew 42% YoY due to investments in branded generics; management expects mid-teen growth for FY26, keeping EBITDA margin in check.
medium · data_observation